![]() ![]() He earned a Bachelor of Science in biology, a medical degree from Loyola University of Chicago, and a Master of Public Health from the University of Illinois at Chicago. ![]() Afable served as the chief medical officer of Catholic Health East from 1999 to 2005. Prior to Hoag Memorial Hospital Presbyterian, Dr. Afable served as the president and chief executive of Hoag Memorial Hospital Presbyterian from 2005 to 2013. Afable served as the chief executive officer of Covenant Health Network, based in Irvine, California, a non-profit healthcare delivery system formed through the affiliation of Hoag Memorial Hospital Presbyterian and St. Afable has served as executive vice president and chief executive, Southern California, for Providence St. ![]() From July 2016 through December 2017, Dr. Joseph Health since January 2018, and he is the immediate past chair of the California Hospital Association. Afable has served as trustee of Chapman University since March 2017, of Providence St. Afable has served as a director on the AcelRx board since 2013. Adams graduated from the Royal Institute of Chemistry at Salford University in the UK. During his tenure he led the transformation of Kos into a fully integrated and profitable pharmaceutical company with annual revenues approaching $1 billion. from 2002 until the acquisition of the company by Abbott Laboratories in December 2006. Adams was president and chief executive officer of Kos Pharmaceuticals, Inc. ![]() Under his leadership, Sepracor conducted multiple strategic corporate development activities, including the in-licensing of seven products and out-licensing deals with two major pharmaceutical companies, prior to its acquisition by Dainippon Sumitomo Pharma Co. Adams served as president and chief executive officer of Sepracor Inc. Adams served as president and chief executive officer of Inspire Pharmaceuticals, Inc., where he oversaw the commercialization and development of prescription pharmaceutical products and led the company through a strategic acquisition by global pharmaceutical leader Merck & Co., Inc. Adams served as chairman and chief executive officer of Neurologix, a company focused on development of multiple innovative gene therapy development programs. Prior to joining Auxilium, from September 2011 until November 2011, Mr. until it was acquired by Endo International plc. Adams served as chief executive officer and president of Auxilium Pharmaceuticals Inc. From December 2011 until January 2015, Mr. Adams served as chief executive officer and a member of the board of directors of Pozen, Inc. Prior to that, from May 2015 to January 2016, Mr. from February 2016 to January 2019 and served as a member of the board of directors from February 2016 to April 2019. Adams served as chief executive officer of Aralez Pharmaceuticals, after the merger between Pozen, Inc. Adams has served as chairman of the board of directors of Akebia Therapeutics, Inc. Adams has also served as chairman of the board of directors of Impel NeuroPharma, Inc., and in May 2020 he took on the additional role of chief executive officer. Adams has served as the Chairman of the AcelRx board of directors since February 2013. ![]()
0 Comments
Leave a Reply. |